An Open-Label, Multi-Center, Single-Arm Study to Evaluate the Efficacy of Nilotinib in Adult Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumors in First Line Treatment
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 30 Oct 2017
At a glance
- Drugs Nilotinib (Primary)
- Indications Gastrointestinal stromal tumours
- Focus Therapeutic Use
- Sponsors Novartis; Novartis Pharmaceuticals
- 21 Mar 2016 Planned End Date changed from 1 Dec 2015 to 1 Dec 2017 as per ClinicalTrials.gov record.
- 21 Mar 2016 Planned primary completion date changed from 1 Dec 2015 to 1 Dec 2017 as per ClinicalTrials.gov record.
- 03 Jul 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.